REQUEST A DEMO
Total
USD $0.00
Search more companies

Sk Biopharmaceuticals Co.,Ltd. (Seongnam) (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Sk Biopharmaceuticals Co.,Ltd. Profile Updated: August 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business. The Company was founded on April1 , 2011 and its shares are listed on Korea Stock Exchaneg on July 2, 2020.

Headquarters
221, Pangyoyeok-Ro, Bundang-Gu
Seongnam; Gyeonggi;

Contact Details: Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.

Website: http://www.skbp.com

Basic Information
Total Employees:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Outstanding Shares:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Registered Capital:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Financial Auditors:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Incorporation Date:
April 01, 2011
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
에스케이
Company Performance
Financial values in the chart are available after Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
79.95%
Total operating revenue
55.37%
Operating profit (EBIT)
N/A
EBITDA
N/A
Net Profit (Loss) for the Period
N/A
Total assets
30.57%
Total equity
27.35%
Operating Profit Margin (ROS)
N/A
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Debt to Equity Ratio
2.16%
Quick Ratio
-0.39%
Cash Ratio
0.25%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?